Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50 Million on August 31, 2026 ADSs clinical development Dilution technique financing characteristics Netherton Syndrome private placement QNRX QRX003 Quoin Pharmaceuticals +
Vivek Ramaswamy-backed Ambros Therapeutics to go public through Werewolf reverse merger on August 24, 2026 6-amino-1-hydroxyhexane-1,1-diphosphonate Ambros Therapeutics Complex Regional Pain Syndromes CRPS-1 Nasdaq private placement reverse merger Vivek Ramaswamy Werewolf Therapeutics +
Slate Uses Fulcrum to Join Nasdaq With $245M Financing for Migraine Trials on August 17, 2026 Capital Management Forbion Frazier Life Sciences Fulcrum Therapeutics migraine prevention private placement reverse merger Rheumatoid Arthritis Slate Medicines SLTE +
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement on June 18, 2026 Alvotech biosimilar medicines Concurrent development aspects Options private placement public entity research underwriters working capital +
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update on March 31, 2026 acquisition Faeth financial results Malignant neoplasm of breast Malignant neoplasm of endometrium PIKTOR private placement Sensei Biotherapeutics +
Sarepta Extends $700M Debt to 2030, Adds Private Placement Amid Elevidys Uncertainty on August 23, 2025 Biopharma convertible debt maturity extension Elevidys financial strategy Note (document) private placement +